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Abstract
Background/Aims: The antiviral drug Elvitegravir is used for the treatment of Human 
Immunodeficiency Virus (HIV) infections. The present study explored whether the drug 
is able to trigger eryptosis, the suicidal death of erythrocytes. Eryptosis is characterized 
by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to 
the erythrocyte surface. Stimulators of eryptosis include increase of cytosolic Ca2+ activity 
([Ca2+]i), oxidative stress, ceramide, activated p38 kinase and activated caspases. The present 
study explored, whether Elvitegravir induces eryptosis and, if so, to shed light on the mechanisms 
involved. Methods: Phosphatidylserine abundance at the erythrocyte surface was estimated 
from annexin-V-binding, cell volume from forward scatter, [Ca2+]i from Fluo3-fluorescence, 
abundance of reactive oxygen species (ROS) from DCFDA dependent fluorescence, and 
ceramide abundance at the erythrocyte surface utilizing specific antibodies. Results: A 48 
hours exposure of human erythrocytes to Elvitegravir (≥ 1.5 µg/ml) significantly increased 
the percentage of annexin-V-binding cells, and significantly decreased forward scatter. 
Elvitegravir (2.5 µg/ml) significantly increased Fluo3-fluorescence, but did not significantly 
modify DCFDA fluorescence or ceramide abundance. The effect of Elvitegravir on annexin-
V-binding was significantly blunted by removal of extracellular Ca2+, but not in the presence 
of p38 kinase inhibitor SB203580 (2 µM) or in the presence of pancaspase inhibitor zVAD (10 
µM). Conclusions: Elvitegravir triggers cell shrinkage and phospholipid scrambling of the 
erythrocyte cell membrane, an effect in part due to entry of extracellular Ca2+.
IntroductionThe viral integrase inhibitor [1] Elvitegravir is an antiretroviral drug [1-5] used for the 
treatment of Human Immunodeficiency Virus (HIV) infections [1, 2, 4-16]. 
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Several related other antiviral drugs, such as nelfinavir [17], saquinavir [18] and 
lopinavir [19] have been shown to trigger eryptosis, the suicidal death of erythrocytes 
characterized by cell shrinkage [20] and cell membrane scrambling with phosphatidylserine 
translocation to the cell surface [21]. Signaling underlying stimulation of eryptosis include Ca2+ entry with increase of cytosolic Ca2+ activity ([Ca2+]i) [21], ceramide [22], caspases [21, 
23, 24], as well as several kinases including casein kinase 1α, Janus-activated kinase JAK3, 
protein kinase C, and p38 kinase [21]. Eryptosis is inhibited by AMP activated kinase AMPK, 
cGMP-dependent protein kinase, PAK2 kinase, mitogen- and stress-activated kinase MSK1/2 
and sorafenib/sunitinib sensitive kinases [21, 25]. Eryptosis is triggered by oxidative stress 
[21], energy depletion [21] and a wide variety of xenobiotics [18, 21, 26-55]. 
The present study explored, whether Elvitegravir stimulates eryptosis. To this end, 
human erythrocytes drawn from healthy volunteers were treated with Elvitegravir and 
phosphatidylserine surface abundance, cell volume, [Ca2+]i, abundance of reactive oxygen 
species (ROS) and ceramide determined by flow cytometry. 
Materials and Methods 
Erythrocytes, solutions and chemicals
Fresh Li-Heparin-anticoagulated blood samples were kindly provided by the blood bank of the University 
of Tübingen. The study is approved by the ethics committee of the University of Tübingen (184/2003 V). The 
blood was centrifuged at 120 x g for 20 min at 21 °C and the platelets and leukocytes-containing supernatant 
was disposed. Erythrocytes were incubated for 48 hours at 37°C in vitro at a hematocrit of 0.4% in Ringer 
solution containing (in mM) 125 NaCl, 5 KCl, 1 MgSO
4
, 32 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid 
(HEPES; pH 7.4), 5 glucose, and 1 CaCl
2
. Where indicated, erythrocytes were exposed for 48 hours to Elvitegravir 
(MedChem Express, Princeton, USA). To test for an involvement of p38 kinase, erythrocytes were exposed for 
48 hours to a combination of Elvitegravir and p38 kinase inhibitor SB203580 (Tocris bioscience, Bristol, UK). 
To test for an involvement of caspases, erythrocytes were exposed for 48 hours to a combination of Elvitegravir 
and pancaspase inhibitor zVAD (Tocris bioscience, Bristol, UK).
Annexin-V-binding and forward scatter 
After incubation under the respective experimental condition, a 150 µl cell suspension was 
washed in Ringer solution containing 5 mM CaCl
2
 and then stained with Annexin-V-FITC (1:200 dilution; 
ImmunoTools, Friesoythe, Germany) in this solution at 37°C for 15 min under protection from light. The 
annexin-V-abundance at the erythrocyte surface was subsequently determined on a FACS Calibur (BD, 
Heidelberg, Germany). Annexin-V-binding was measured in FL-1 with an excitation wavelength of 488 nm 
and an emission wavelength of 530 nm. A marker (M1) was placed to set an arbitrary threshold between 
annexin-V-binding cells and control cells. The same threshold was used for untreated and Elvitegravir 
treated erythrocytes. A dot plot of forward scatter (FSC) vs. side scatter (SSC) was set to linear scale for both 
parameters. The threshold of forward scatter was set at the default value of “52”.
Intracellular Ca2+
After incubation, erythrocytes were washed in Ringer solution and then loaded with Fluo-3/AM 
(Biotium, Hayward, USA) in Ringer solution containing 5 mM CaCl
2
 and 5 µM Fluo-3/AM. The cells were 
incubated at 37°C for 30 min and washed once in Ringer solution containing 5 mM CaCl
2
. The Fluo-3/
AM-loaded erythrocytes were resuspended in 200 µl Ringer solution. Then, Ca2+-dependent fluorescence 
intensity was measured in FL-1 with an excitation wavelength of 488 nm and an emission wavelength of 
530 nm on a FACS Calibur. Afterwards, the geomean of the Ca2+ dependent fluorescence was determined.
Reactive oxidant species (ROS) 
Oxidative stress was determined utilizing 2’,7’-dichlorodihydrofluorescein diacetate (DCFDA). After 
incubation, a 150 µl suspension of erythrocytes was washed in Ringer solution and then stained with DCFDA 
(Sigma Aldrich, Hamburg, Germany) in Ringer solution containing DCFDA at a final concentration of 10 µM. 
Erythrocytes were incubated at 37°C for 30 min in the dark and then washed two times in Ringer solution. The 
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DCFDA-loaded erythrocytes were resuspended in 200 µl Ringer solution, and ROS-dependent fluorescence 
intensity was measured in FL-1 at an excitation wavelength of 488 nm and an emission wavelength of 530 nm on a FACS Calibur (BD). Subsequently, the geomean of the ROS-dependent fluorescence was determined
Ceramide abundance
To determine the ceramide abundance at the erythrocyte surface, a monoclonal antibody was used. 
After incubation, cells were stained for 1 h at 37°C with 1μg/ml anti-ceramide antibody (clone MID 15B4; 
Alexis, Grünberg, Germany) in phosphate-buffered saline (PBS) containing 0.1 % bovine serum albumin 
(BSA) at a dilution of 1:10. After two washing steps with PBS-BSA, cells were stained for 30 min with 
polyclonal fluorescein-isothiocyanate (FITC)-conjugated goat anti-mouse IgG and IgM specific antibody 
(BD Pharmingen, Hamburg, Germany) diluted 1:50 in PBS-BSA. Unbound secondary antibody was removed 
by repeated washing with PBS-BSA. Samples were then analyzed by flow cytometric analysis in FL-1 at 
an excitation wavelength of 488 nm and an emission wavelength of 530 nm. Finally, the geomean of the 
ceramide dependent fluorescence was determined.
Statistics
Data are expressed as arithmetic means ± SEM. As indicated in the figure legends, statistical analysis 
was made using ANOVA with Tukey’s test as post-test and t test as appropriate. n denotes the number of 
different erythrocyte specimens studied. Since different erythrocyte specimens used in distinct experiments 
are differently susceptible to triggers of eryptosis, the same erythrocyte specimens have been used for control 
and experimental conditions.
Results
The present study tested whether Elvitegravir stimulates eryptosis, the suicidal 
erythrocyte death characterized by cell shrinkage and by phospholipid scrambling of the 
cell membrane with phosphatidylserine translocation to the cell surface. 
Erythrocyte volume was estimated from forward scatter, which was determined 
utilizing flow cytometry. Prior to measurements, the erythrocytes were incubated for 48 
hours in Ringer solution without or with Elvitegravir (0.5 – 2.5 µg/ml). As illustrated in Fig. 1, 
Elvitegravir decreased erythrocyte forward scatter, an effect reaching statistical significance 
at 1.5 µg/ml Elvitegravir concentration. 
Phosphatidylserine exposing erythrocytes were identified utilizing annexin-V-binding, 
as determined by flow cytometry. Prior to measurements, the erythrocytes were again 
Fig. 1. Effect of Elvitegravir on erythrocyte forward scatter. A. Original histogram of forward scatter 
of erythrocytes following exposure for 48 hours to Ringer solution without (grey area) and with (black 
line) presence of 2.5 µg/ml Elvitegravir. B. Arithmetic means ± SEM (n = 10) of the erythrocyte forward 
scatter (FSC) following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) 
Elvitegravir (0.5 - 2.5 µg/ml). For comparison, the effect of the solvent DMSO is shown (grey bar). *(p<0.05), 
***(p<0.001) indicate significant difference from the absence of Elvitegravir (ANOVA).
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incubated for 48 hours in Ringer solution without or with Elvitegravir (0.5 – 2.5 µg/ml). 
As illustrated in Fig. 2, a 48 hours exposure to Elvitegravir increased the percentage of 
phosphatidylserine exposing erythrocytes, an effect reaching statistical significance at 1.5 
µg/ml Elvitegravir. 
Fluo3 fluorescence was taken as a measure of cytosolic Ca2+ activity ([Ca2+]i). As 
illustrated in Fig. 3, a 48 hours exposure to 2.5 µg/ml Elvitegravir significantly increased the 
Fluo3 fluorescence, an observation pointing to increase of [Ca2+]i.
A next series of experiments explored whether the Elvitegravir-induced translocation 
of phosphatidylserine was sensitive to extracellular Ca2+. To this end, erythrocytes were 
incubated for 48 hours in the absence or presence of 2.5 µg/ml Elvitegravir in the presence 
or nominal absence of extracellular Ca2+. As shown in Fig. 4, removal of extracellular Ca2+ 
significantly blunted the effect of Elvitegravir on the percentage of annexin-V-binding 
erythrocytes. However, even in the absence of extracellular Ca2+, Elvitegravir significantly 
increased the percentage of annexin-V-binding erythrocytes. Thus, Elvitegravir-induced cell 
shrinkage was in part, but not fully due to entry of extracellular Ca2+.Eryptosis is further stimulated by oxidative stress. Reactive oxygen species (ROS) was 
thus quantified utilizing 2′,7′-dichlorodihydrofluorescein diacetate (DCFDA). As a result, the 
Fig. 2. Effect of Elvitegravir on phosphatidylserine 
exposure. A. Original histogram of annexin-V-
binding of erythrocytes following exposure for 48 
hours to Ringer solution without (grey area) and 
with (black line) presence of 2.5 µg/ml Elvitegravir. 
B. Arithmetic means ± SEM (n = 10) of erythrocyte 
annexin-V-binding following incubation for 48 hours 
to Ringer solution without (white bar) or with (black 
bars) Elvitegravir (0.5 - 2.5 µg/ml). For comparison, 
the effect of the solvent DMSO is shown (grey 
bar). **(p<0.01),***(p<0.001) indicate significant 
difference from the absence of Elvitegravir (ANOVA).
Fig. 3. Effect of Elvitegravir on cytosolic Ca2+ 
activity. A. Original histogram of Fluo3 fluorescence 
of erythrocytes following exposure for 48 hours to 
Ringer solution without (grey area) and with (black 
line) presence of 2.5 µg/ml Elvitegravir. B. Arithmetic 
means ± SEM (n = 10) of Fluo3 fluorescence in 
erythrocytes following incubation for 48 hours to 
Ringer solution without (white bar) or with (black 
bars) Elvitegravir (0.5 - 2.5 µg/ml). For comparison, 
the effect of the solvent DMSO is shown (grey bar). 
*(p<0.05) indicates significant difference from the 
absence of Elvitegravir (ANOVA).
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DCFDA fluorescence was similar following exposure to 2.5 µg/ml Elvitegravir (17.7 ± 0.8 a.u., 
n = 11) and in the absence of Elvitegravir (16.9 ± 0.8 a.u., n = 11). Thus, Elvitegravir did not 
appreciably induce oxidative stress.
A further stimulator of eryptosis is ceramide. Ceramide abundance at the erythrocyte 
surface was thus quantified utilizing specific antibodies. As a result, the ceramide abundance 
was similar following exposure to 2.5 µg/ml Elvitegravir (16.6 ± 0.7 a.u., n = 11) and in the 
absence of Elvitegravir (16.7 ± 0.7 a.u., n = 11). Thus, Elvitegravir did not appreciably induce 
ceramide abundance.
To explore, whether the effects of Elvitegravir involved p38 kinase activity, the influence 
of Elvitegravir on annexin-V-binding was tested in the absence or presence of p38 kinase 
inhibitor SB203580 (2 µM). As a result, Elvitegravir (2.5 µg/ml) increased the percentage 
of phosphatidylserine exposing erythrocytes to similar values in the absence (from 2.1 ± 
0.1 % to 20.8 ± 1.5 %, n = 5) and in the presence (from 2.4 ± 0.2 % to 21.6 ± 1.5 %, n = 5) of 
SB203580 (2 µM). 
A final series of experiments addressed the putative involvement of caspases in 
Elvitegravir induced eryptosis. To this end, the influence of Elvitegravir on annexin-V-
binding was tested in the absence or presence of pancaspase inhibitor zVAD (10 µM). As 
a result, Elvitegravir (2.5 µg/ml) increased the percentage of phosphatidylserine exposing 
erythrocytes to similar values in the absence (from 2.4 ± 0.7 % to 21.8 ± 2.1 %, n = 5) and in 
the presence (from 2.0 ± 0.5 % to 21.7 ± 2.5 %, n = 5) of zVAD (10 µM). 
Fig. 4. Ca2+ sensitivity of Elvitegravir-induced phosphatidylserine exposure. A,B. Original histogram of 
annexin-V-binding of erythrocytes following exposure for 48 hours to Ringer solution without (grey area) 
and with (black line) Elvitegravir (2.5 µg/ml) in the presence (A) and absence (B) of extracellular Ca2+. C. 
Arithmetic means ± SEM (n = 11) of annexin-V-binding of erythrocytes after a 48 hours treatment with 
Ringer solution without (white bars) or with (black bars) Elvitegravir (2.5 µg/ml) in the presence (left bars, 
+Ca2+) and absence (right bars, -Ca2+) of Ca2+. ***(p<0.001) indicates significant difference from the absence 
of Elvitegravir, ##(p<0.01) indicates significant difference from the presence of Ca2+  (ANOVA).
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Discussion
The present observations reveal a novel effect of Elvitegravir, i.e. the stimulation of eryptosis, 
the suicidal erythrocyte death. Treatment of erythrocytes from healthy individuals with 
Elvitegravir results in cell shrinkage and cell membrane scrambling with phosphatidylserine 
translocation to the erythrocyte surface. The concentrations required for this effect are in 
the range of peak plasma concentrations determined in Elvitegravir treated patients [56]. 
A single dose of 150 mg of Elvitegravir has been shown to be followed by an increase of the 
plasma Elvitegravir concentration to 2.3 µg/ml and a subsequent decline of the plasma 
Elvitegravir concentration to 0.5 µg/ml [56]. At least in theory, the sensitivity to Elvitegravir 
induced eryptosis could be enhanced in clinical conditions with accelerated eryptosis, 
such as dehydration [57], hyperphosphatemia [58], chronic kidney disease (CKD) [59-62], 
hemolytic-uremic syndrome [63], diabetes [64], hepatic failure [65], malignancy  [21], sepsis 
[66], sickle-cell disease [21], beta-thalassemia [21], Hb-C and G6PD-deficiency [21], as well 
as Wilsons disease [67].
The effect of Elvitegravir on cell membrane scrambling was blunted by removal of Ca2+ 
from the extracellular space, indicating that the effect was partially dependent on entry of 
extracellular Ca2+.  The effect of Elvitegravir on cell shrinkage was presumably as well partially due to Ca2+ entry from the extracellular space leading to increase of [Ca2+]i with subsequent 
activation of Ca2+ sensitive K+ channels, K+ exit, cell membrane hyperpolarization, Cl- exit and 
thus cellular loss of KCl with water [20].
However, Elvitegravir triggered cell membrane scrambling even in the absence of 
extracellular Ca2+, indicating that Elvitegravir triggered cell membrane scrambling in part 
by mechanisms other than Ca2+ entry. Additional mechanisms triggering eryptosis include 
oxidative stress, ceramide, activation of p38 kinase or stimulation of caspases [21]. However, 
Elvitegravir triggered cell membrane scrambling and cell shrinkage without enhancing the 
ceramide abundance and without inducing oxidative stress. Moreover, the effect of Elvitegravir 
was insensitive to inhibition of p38 kinase with SB203580 and to inhibition of caspases with 
zVAD. Thus, the additional mechanism involved in the triggering of eryptosis other than Ca2+ 
entry remained elusive.   
Eryptosis allows the clearance of defective erythrocytes from circulating blood prior 
to hemolysis [21]. Avoidance of hemolysis is important as hemolysis leads to release of 
hemoglobin, which passes the renal glomerular filter, precipitates in the acidic lumen of 
renal tubules, occludes nephrons and thus may lead to renal failure [68]. Eryptosis further 
counteracts development of parasitemia in malaria, as it is triggered by infection of host 
erythrocytes and accomplishes elimination of infected erythrocytes. 
The clearance of phosphatidylserine exposing erythrocytes from circulating blood 
may lead to anemia if the loss of erythrocytes outcasts the formation of new erythrocytes 
by erythropoiesis [21]. Phosphatidylserine exposing erythrocytes further adhere to the 
vascular wall [69], stimulate blood clotting and thus foster thrombosis [70-72]. Accordingly, 
stimulation of eryptosis may lead to impairment of microcirculation [22, 70, 73-76]. 
In conclusion, Elvitegravir triggers eryptosis with cell shrinkage and cell membrane 
scrambling, an effect in part due to Ca2+ entry.  
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